Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board
Retrieved on:
Thursday, April 11, 2024
University, Agriculture, SAB, RNA interference, Biochemistry, Research, Central Waqf Council, State university system, Business administration, RNA, Danisco, Doctor of Philosophy, Cell, Molecular biology, Genencor, Chemical engineering, Buffalo, Therapy, Senior, Cobalt, Patient, Cobalt Technologies, Bachelor, ECO, Codexis, Green-light, MBA, Biotechnology, Management
REDWOOD CITY, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of Carole Cobb, MBA, to the Company’s Strategic Advisory Board (SAB).
Key Points:
- REDWOOD CITY, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of Carole Cobb, MBA, to the Company’s Strategic Advisory Board (SAB).
- Ms. Cobb is the former Chief Operating Officer at GreenLight Biosciences, a bio-performance company developing RNA-based solutions for agriculture and pharmaceutical applications.
- Her deep biotechnology experience includes leadership roles across fermentation-based commercial manufacturing, process development, plant operations and global supply chain management.
- “We are honored to have Carole join Codexis as the newest member of our Strategic Advisory Board,” said Stefan Lutz, PhD, Senior Vice President of Research at Codexis.